Boardroom Alpha
Boardroom Alpha
ACA · Current Report (Form 8-K) · Filed May 15, 2026

Arcosa Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 15, 2026
Period
May 13, 2026
Ticker
ACA
Accession
0001739445-26-000093
Boardroom Alpha · Filing insights

Shareholders elected directors to serve until the 2027 annual meeting; advisory executive compensation approved; Ernst & Young ratified as auditor.

About Arcosa Inc
Market cap
$6.0B
1Y TSR
+43.9%
3Y TSR
+20.5%
Board grade
C
Sector
Industrials
CEO
Antonio Carrillo
Last annual meeting: May 13, 2026 · View full Arcosa Inc profile →
aca-20260513

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 13, 2026
arcosalogo-orangea06.jpg
Arcosa, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware1-3849482-5339416
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    
500 N. Akard Street, Suite 400
Dallas,Texas75201
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (972) 942-6500
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.01 par value)ACANew York Stock Exchange
Common Stock ($0.01 par value)ACANYSE Texas, Inc.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.07    Submission of Matters to a Vote of Security Holders.
On May 13, 2026, the Company held its 2026 Annual Meeting of Shareholders at which the Company’s shareholders voted on the following three proposals and cast their votes as described below.
Proposal 1 – Election of Directors
The shareholders elected the following Directors to serve a term expiring at the 2027 annual meeting of shareholders:
NomineeForAgainstAbstentionsBroker Non-Votes
Joseph Alvarado44,059,859211,88815,4802,586,744
Rhys J. Best44,091,957179,93715,3332,586,744
Antonio Carrillo44,003,636269,02014,5712,586,744
Jeffrey A. Craig44,130,284141,78815,1552,586,744
Steven J. Demetriou40,843,3913,427,28916,5472,586,744
John W. Lindsay44,158,115114,49314,6192,586,744
Kimberly S. Lubel44,074,968191,54420,7152,586,744
Julie A. Piggott44,077,761185,87723,5892,586,744
Melanie M. Trent41,980,4382,290,04016,7492,586,744
Proposal 2 – Advisory Vote to Approve Named Executive Officer Compensation
The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement dated March 31, 2026, including the Compensation Discussion and Analysis, the compensation tables, and the narrative discussion related thereto, by the following vote:
ForAgainstAbstentionsBroker Non-Votes
43,665,451521,91799,8592,586,744
Proposal 3 – Ratification of Appointment of Independent Registered Public Accounting Firm for the Year Ending December 31, 2026
The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following vote:
ForAgainstAbstentions
46,578,461264,35331,157


Item 9.01     Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Arcosa, Inc.
(Registrant)
May 15, 2026By:/s/ Bryan P. Stevenson
Name: Bryan P. Stevenson
Title: Chief Legal Officer


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Arcosa Inc (ACA)

Reference

Frequently asked questions

When did Arcosa Inc file this 8-K?
Arcosa Inc (ACA) filed this Current Report (Form 8-K) with the SEC on May 15, 2026. The accession number assigned by EDGAR is 0001739445-26-000093.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Shareholders elected directors to serve until the 2027 annual meeting; advisory executive compensation approved; Ernst & Young ratified as auditor. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Arcosa Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Arcosa Inc has filed under CIK 1739445, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer